|
71 |
Cost-Effectiveness of Early Treatment with Originator Biologics or Their Biosimilars After Methotrexate Failure in Patients with Established Rheumatoid Arthritis
Enthalten in Advances in therapy Bd. 36, 30.5.2019, Nr. 8, date:8.2019: 2086-2095
|
|
|
|
72 |
Cross-Switch from Etanercept Originator to Biosimilar SB4 and to GP2015 in Patients with Chronic Plaque Psoriasis
Enthalten in BioDrugs Bd. 35, 11.5.2021, Nr. 4, date:7.2021: 469-471
|
|
|
|
73 |
Discontinuation and Switchback After Non-Medical Switching from Originator Tumor Necrosis Factor Alpha (TNF) Inhibitors to Biosimilars: A Meta-Analysis of Real-World Studies from 2012 to 2018
Enthalten in Advances in therapy Bd. 39, 23.6.2022, Nr. 8, date:8.2022: 3711-3734
|
|
|
|
74 |
Discrepancies Between the Labels of Originator and Generic Pharmaceutical Products: Implications for Patient Safety
Enthalten in Drugs - real world outcomes Bd. 7, 22.4.2020, Nr. 2, date:6.2020: 131-139
|
|
|
|
75 |
Disease remission and sustained remission after etanercept biosimilar or originator initiation in rheumatoid arthritis: an interim real-world analysis
Enthalten in Arthritis Research & Therapy Bd. 27, 17.7.2025, Nr. 1, date:12.2025: 1-7
|
|
|
|
76 |
Economic Impact of Non-Medical Switching from Originator Biologics to Biosimilars: A Systematic Literature Review
Enthalten in Advances in therapy Bd. 36, 5.6.2019, Nr. 8, date:8.2019: 1851-1877
|
|
|
|
77 |
Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic Kidney Disease in a Large-Scale Italian Cohort Study
Enthalten in Drug safety Bd. 42, 21.6.2019, Nr. 12, date:12.2019: 1437-1447
|
|
|
|
78 |
Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC)
Enthalten in BioDrugs Bd. 35, 15.7.2021, Nr. 4, date:7.2021: 417-428
|
|
|
|
79 |
Efficacy and safety of biosimilar Peg-filgrastim after autologous stem cell transplant in myeloma and lymphoma patients: a comparative study with biosimilar Filgrastim, Lenograstim, and originator Peg-filgrastim
Enthalten in Annals of hematology Bd. 103, 8.1.2024, Nr. 3, date:3.2024: 947-956
|
|
|
|
80 |
Efficacy and safety of biosimilar versus originator infliximab in patients with inflammatory bowel disease: A real-world cohort analysis
Enthalten in Indian journal of gastroenterology Bd. 41, 15.11.2022, Nr. 5, date:10.2022: 446-455
|
|
Administration
